Anti-cancer activity of lavender oil and Newcastle disease virus on human glioblastoma: an in vitro study
DOI:
https://doi.org/10.56714/bjrs.49.1.1Keywords:
Anti-cancer activity, cell lines, Lavender oil, NDVAbstract
Glioblastoma is one of the most prevalent brain tumors and was the leading cause of cancer death. Since this cancer is an aggressive, incredibly invasive, and neurologically debilitating tumor that does not respond well to chemotherapy, a group of researchers looked at alternative, more efficient therapies. The current study focused on using biological agents and their products (Lavender essential oil and Newcastle disease virus(NDV)) to test their toxicity against the human cerebral glioblastoma (AMGM-5) as a cancer cell model by 3-(4, 5- dimethylthiazol-2-yl-2-) 2.5- diphenyltetrazolium bromide (MTT) viability assay. In brief, the cells were exposed to several concentrations of lavender oil and serial multiplicity of infection (MOI) of NDV for 72 hours. The result shows significantly decreased cell viability treated with lavender oil and NDV in a concentration-dependent manner. The inhibitory concentration that kills 50% of the cells (IC50) of lavender oil was 4.471µg/ml, and the IC50 value of NDV was 0.00473MOI. Also, the morphological study was conducted by the traditional method by using hematoxylin & eosin (H&E) and apoptotic assay by using Acridine orange/Ethidium bromide (AO/EB), the changes are apoptosis and degeneration, as well as cell the emergence of necrotic cells. The compounds of lavender oil were probably responsible for the cytotoxicity of lavender oil. Our results revealed the antagonistic effect of combined essential oil and NDV. Essential oil and NDV have the same toxicity potential for glioblastoma.
Downloads
References
T. Yamaguchi, Y. Kinugasa, A. Shiomi, H. Tomioka, H. Kagawa and Y. Yamakawa, Surg. today, 8(46), 957 (2016).
Y. Q. Yao, X. Ding, Y. C. Jia, C. X. Huang, Y. Z. Wang and Y. H. Xu, Cancer lett., 264(1), 127 (2008).
P. G. Prasanna, H. B. Stone, R. S. Wong, J. Capala, E. J. Bernhard, B. Vikram and C. N. Coleman, Transl. Cancer Res., 1(1), 35 (2012).
M. Rafieian-Kopaie and H. Nasri, Int. J. Prev. Med., (6), (2015).
L. Ouyang, Y. Luo, M. Tian; S. Y. Zhang, R. Lu, J. H. Wang and X.Li, Cell Prolif., 6(47), 506 (2014).
H. Wang, T. Khor, L. Shu, Z. Y. Su, F. Fuentes, J. H. Lee and A. N. Tony Kong, Curr. Med. Chem. Anticance., 10(12), 1281 (2012).
R. Ahmad, N. Ahmad, A. A. Naqvi, A. Shehzad and M. S. Al-Ghamdi, J. Tradit. Complement. Med., 2(7), 195 (2017).
S. Gezici, Ann. Phytomed., 2(7), 38 (2018).
P. Hossein Koulivand, M. Khaleghi Ghadiri, and A. Gorji, Evid. Based Complementary Altern. Med., 2013.
H. Fukuhara, Y. Ino, and T. Todo, Cancer Sci., 10(107), 10 (2016).
M. Mondal, J. Guo, P. He and D. Zhou, Hum. Vaccin. Immunother., 10(16), 2389 (2020).
A. M. Al-Shammari, W. N. Al-Esmaeel, A. A. A. Al Ali; A. A. Hassan and A. A. Ahmed, mol. Ther., 4(27), 126 (2019).
Y. Yu, M. Shen, Q. Song and J. Xie, Carbohydr. Polym.,(183), 91 (2018).
K. Blowman, M. Magalhães, M. Lemos, C. Cabral and I. Pires, Evid. Based Complementary Altern. Med., 2018.
K. von Schwarzenberg and A. M. Vollmar, Cancer lett., 2(332), 295 (2013).
M. Lis-Balchin and S. Hart, Phytother. Res., 6(13), 540 (1999).
S. M. Falih, S. T. Al-Saray, A. A. Alfaris, and A. A. Al-Ali, Egypt. J. Med. Hum. Genet., 1(23), 1 (2022).
A. N. AbbasAllaftah and A. A. Y. AlHassan, AIP Conf. Proc., 1(2386), (2022).
M. A. Fahmy, A. A. Farghaly, E. E. Hassan, E. M. Hassan,Z. M. Hassan, K. Mahmoud and E. A. Omara, Asian Pac J Cancer Prev, 4(23), 1215 (2022).
Y. Zhao, R. Chen, Y. Wang, C. Qing, W. Wang and Y. Yang, Integr. Cancer Ther., 2(16), 215 (2017).
M. Sienkiewicz, A. Głowacka, E. Kowalczyk, A. Wiktorowska-Owczarek, M. Jóźwiak-Bębenista and M. Łysakowska, Mol., 12(19), 20929 (2014).
M. J. Vähä-Koskela, J. E. Heikkilä and A. E. Hinkkanen, Cancer lett., 2(254), 178 (2007).
M. Keshavarz, A. S. M. Nejad, M. Esghaei, F. Bokharaei-Salim, H. Dianat-Moghadam, H, Keyvani and A. Ghaemi, Saudi J. Biol. Sci., 1(27), 47 (2020).
S. A. Hassan, A. B. Allawe and A. M. Al-Shammari, Iraqi J. Sci., 285 (2020).
K. S. Yurchenko, P. Zhou, A. V. Kovner, E.L. Zavjalov, L. V. Shestopalova and A.M. Shestopalov, PLoS One, 4(13), e0195425 (2018).
I. Ahmed, U. Ahmad, Y. Keong, N. Manna and F. Othman, J. Cancer Sci. Ther., (6), 478 (2014).
A. G. Al-Ziaydi, A. M. Al-Shammari, M. I. Hamzah, H. S. Kadhim and M.S. Jabir, Virusdisease, 3(31), 341 (2020).
T. E. Ginting, J. Suryatenggara, S. Christian and G. Mathew, Oncolytic virotherapy, (6), 21 (2017).
A. M. Al-Shammari, R. D. A. Jalill and M.F. Hussein, Mol. Biol. Rep, 3(47), 1691 (2020).
D. Mieres-Castro, S. Ahmar; R. Shabbir and F. Mora-Poblete, Pharmaceuticals, 12(14), 1210 (2021).
D. H. Abou Baker, R. Amarowicz, A. Kandeil, M. A. Ali and E. A. Ibrahim, J. agricultural sci. food res., (4), 100135 (2021).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Zainab K. Shaheen, Ali A. Al-Ali, Sarmad A. Al-Asadi
This work is licensed under a Creative Commons Attribution 4.0 International License.
